证券代码：301509 证券简称：金凯生科 公告编号：2025-022 金凯（辽宁）生命科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）第二届董事会第八 次会议于2025年8月22日上午9时30分在公司会议室以现场会议结合通讯方式召开。 本次会议通知于2025年8月12日以当面送达结合邮件方式发出。在保障所有董事充 分表达意见的情况下，本次会议采用现场结合通讯方式进行表决，会议应到董事7 人，实到董事7人，其中董事LIANPING WU（吴连萍）、董事宋学章以通讯方式出席。 本次会议由董事长FUMIN WANG（王富民）先生主持，公司监事、高级管理人员、保 荐代表人逯金才、张林列席本次会议。本次会议的召开和审议程序符合《中华人民 共和国公司法》等法律、法规和《金凯（辽宁）生命科技股份有限公司章程》的有 关规定。本次会议合法、有效。 董事会经审议认为：公司《2025年半年度报告》及其摘要的编制程序、格式及 内容符合相关法律、法规的规定，真 ...

金凯（辽宁）生命科技股份有限公司 2025 年半年度报告全文 金凯（辽宁）生命科技股份有限公司 2025 年半年度报告 2025-021 2025 年 8 月 1 金凯（辽宁）生命科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 FUMIN WANG（王富民）、主管会计工作负责人王琦及会计机 构负责人(会计主管人员)张秀丽声明：保证本半年度报告中财务报告的真实、 准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异。敬请投资者注意投资风险。 公司是一家面向全球生命科技领域客户的小分子 CDMO 服务商，为世界大 型跨国医药及生物制药集团、创新药公司、化工集团等提供 CDMO 服务。公司 未来经营中可能面临着国际贸易政策环境变化、终端需求波动、生产环保 ...

金凯生科公告，2025年上半年营业收入3.48亿元，同比增长32.98%。净利润7176.06万元，同比增长 123.61%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Group 1: Weight Loss Drug Sector - A-share weight loss drug concept stocks collectively rose, with Hanyu Pharmaceutical increasing over 14% and Jinkai Biotechnology rising over 12% following the FDA's accelerated approval of Novo Nordisk's Wegovy for treating non-alcoholic steatohepatitis in adults [1] - The competition in the GLP-1 weight loss drug sector is intensifying, expanding from weight loss efficacy to related complications like fatty liver disease, indicating a broad market potential [1] Group 2: Shenyuan Biological - Shenyuan Biological's stock experienced two consecutive trading limit increases, but the company clarified that its main business is veterinary biological products, while its innovative drug pipeline, including HIV monoclonal antibodies, is operated independently by a joint venture [2] - Investors are advised to be cautious of stock price fluctuations that may deviate from the company's fundamentals [2] Group 3: Maiwei Biological - Maiwei Biological announced that its ADC innovative drug 7MW4911 received FDA approval to conduct clinical trials for advanced colorectal cancer and other gastrointestinal tumors, marking a significant step in its international drug innovation efforts [3] - The ADC field is highly competitive, and investors should closely monitor the subsequent clinical data for 7MW4911 [3] Group 4: Zhifei Biological - Zhifei Biological reported a net loss of 597 million yuan for the first half of 2025, with revenue declining by 73.06% year-on-year to 4.919 billion yuan, and no cash dividends or stock bonuses planned [4] - The vaccine industry is under pressure due to vaccine hesitancy, fluctuating demand, and intensified competition, making it challenging for Zhifei Biological to reverse its performance difficulties in the short term [4] Group 5: Aimeike - Aimeike's revenue for the first half of 2025 was 1.299 billion yuan, down 21.59% year-on-year, with a net profit decline of 29.57% to 789 million yuan [5] - The company plans to distribute a cash dividend of 12 yuan per 10 shares, and its acquisition of South Korea's REGEN is expected to strengthen its position in the medical beauty injection market amid increasing competition and differentiated consumer demand [5]

8月18日，金凯生科大宗交易成交40万股，成交额1644.8万元，占当日总成交额的2.75%，成交价41.12 元，较市场收盘价41.75元折价1.51%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万龄/万份) (万元) | | | | | 2025-08-18 | 301509 | 金凯生科 | 41.12 | 20.00 | | 822.40 东兴证券股份有限 | 中信证券(山东) | | | | | | | | 公司上海陆家嘴证 券营业部 | 有限责任公司青岛 秦岭路证券营业部 | | 2025-08-18 | 301509 | 金凯生科 | 41.12 | 5.00 | 205.60 | 国泰海通证券股份 | 中信证券(山东) | | | | | | | | 有限公司济南胜利 | 有限责任公司青岛 | | | | | | | | 大街证券营业部 | 秦岭路证券营业部 | | 2025-08-18 ...

证券之星消息，8月18日医疗服务板块较上一交易日上涨0.46%，金凯生科领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300759 | 康龙化成 | 6867.71万 | 4.17% | 415.47万 | 0.25% | -7283.18万 | -4.42% | | 600721 | 百花医药 | 6396.54万 | 25.72% | -2098.21万 | -8.44% | -4298.33万 | -17.28% | | 300015 | 爱尔眼科 | 4784.89万 | 2.60% | -5738.06万 | -3.11% | 953.16万 | 0.52% | | 300683 | 海特生物 | 3249.97万 | 3.98% | -716.30万 | -0.88% ...

Group 1 - The core viewpoint of the news is that the A-share market saw a collective rise in weight-loss drug concept stocks, driven by the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1][2]. - Han Yu Pharmaceutical (300199) experienced a significant increase of over 14%, while other companies like Jin Kai Biotechnology and Shengnuo Bio rose by over 12% and 6% respectively [1][2]. - Novo Nordisk's stock rose over 6% in after-hours trading following the FDA's announcement regarding Wegovy [1]. Group 2 - The following companies showed notable stock performance: - Han Yu Pharmaceutical (300199) with a rise of 14.66% and a total market value of 26.4 billion [2]. - Jin Kai Biotechnology (301509) increased by 12.28% with a market value of 5.1 billion [2]. - Shengnuo Bio (688117) rose by 6.00% and has a market value of 7.229 billion [2]. - Yangguang Nuohuo (688621) increased by 4.37% with a market value of 8.96 billion [2]. - ST Nuotai (688076) rose by 4.08% with a market value of 15 billion [2]. - Other companies like Zhongsheng Pharmaceutical and Kangyuan Pharmaceutical also saw increases close to 4% [1][2].

翰宇药业涨超10%，阳光诺和、金凯生科、乐普医疗涨超5%，百花医药、常山药业、圣诺生物、昊帆 生物、德源药业等跟涨。消息面上，美国FDA已加速批准其重磅疗法Wegovy（2.4 mg司美格鲁肽）的 补充新药申请（sNDA），用于治疗伴有中度至重度肝纤维化（2期或3期）的非肝硬化型代谢功能障碍 相关脂肪性肝炎（MASH）成人患者。受此影响，诺和诺德美股盘后涨超6%。 ...

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., is engaged in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business segments include fluorinated CDMO services (69.58% of revenue) and non-fluorinated CDMO services (29.10%), with minor contributions from trade and technical services [8]. - The company has a significant overseas revenue share of 61.18%, benefiting from the depreciation of the Chinese yuan [4]. Recent Developments - As of August 8, 2023, the company is involved in projects related to the production of intermediates for Semaglutide oral formulations [2]. - The company also provides intermediates for Alzheimer's-related drugs to biopharmaceutical companies in Europe and the U.S. [3]. Financial Performance - For the first quarter of 2025, the company reported a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit of 47.42 million yuan, up 183.24% year-on-year [8]. Market Activity - On August 15, 2023, the company's stock price increased by 1.05%, with a trading volume of 127 million yuan and a turnover rate of 5.95%, leading to a total market capitalization of 4.542 billion yuan [1]. - The stock has seen a net outflow of 7.42 million yuan from major investors, indicating a reduction in holdings over the past two days [5][6]. Technical Analysis - The average trading cost of the stock is 39.15 yuan, with the current price approaching a resistance level of 38.05 yuan, suggesting potential for a price correction if this level is not surpassed [7]. Shareholder Information - As of August 8, 2023, the number of shareholders decreased by 4.76% to 13,700, with an average of 4,136 circulating shares per person, which increased by 4.99% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business segments include fluorinated CDMO services (69.58% of revenue) and non-fluorinated CDMO services (29.10%), with minor contributions from trade and technical services [8]. - The company has a significant overseas revenue share of 61.18%, benefiting from the depreciation of the Chinese yuan [4]. Recent Developments - As of August 8, 2023, the company is involved in projects related to the production of intermediates for Semaglutide oral formulations [2]. - The company also provides intermediates for Alzheimer's-related projects for biopharmaceutical companies in Europe and the United States [3]. Financial Performance - For the first quarter of 2025, the company reported a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit of approximately 47.42 million yuan, up 183.24% year-on-year [8]. Market Activity - On August 14, 2023, the company's stock price fell by 4.41%, with a trading volume of 254 million yuan and a turnover rate of 11.80%, resulting in a total market capitalization of approximately 4.495 billion yuan [1]. - The stock has shown no clear trend in major capital inflows, with a net outflow of 10.79 million yuan on the day [5][6]. Technical Analysis - The average trading cost of the stock is 39.26 yuan, with the current price approaching a resistance level of 38.05 yuan, indicating potential for a price correction if this level is not surpassed [7].